Other languages Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Delayed Nasdaq Other stock markets 11:06:37 2024-05-02 EDT			5-day change	1st Jan Change
2.96 ^USD	+3.86%		+1.08%	+2.42%

02-12	Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
02-07	Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	02-01
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	01-08
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	23-10-24
Acasti Pharma Inc. Announces Board Changes	23-10-11
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing	23-09-28
Acasti Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11
Top Midday Decliners	23-07-07
Acasti Pharma to Implement 1-for-6 Reverse Stock Split	23-07-07
Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol	23-07-05
Acasti Pharma Says it has Aligned With FDA Protocol for Phase 3 Trial of GTX-104; Receives New Drug Application Guidance	23-07-05
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-23
Acasti Pharma Inc. Announces Scientific Advisory Board Appointments	23-06-22
Acasti Pharma Inc. Announces Executive Changes	23-05-11
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025	23-05-08
Acasti Pharma Inc. to Proceed with Phase 3 Clinical Safety Study for GTX-104	23-04-05
Acasti Pharma Inc. Announces CEO Changes	23-04-05
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee	23-03-30
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Other languages

Filters